levodopa has been researched along with rasagiline in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.37) | 18.7374 |
| 1990's | 3 (4.11) | 18.2507 |
| 2000's | 25 (34.25) | 29.6817 |
| 2010's | 32 (43.84) | 24.3611 |
| 2020's | 12 (16.44) | 2.80 |
| Authors | Studies |
|---|---|
| Finberg, JP; Youdim, MB | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Commissiong, JW; Finberg, JP; Lamensdorf, I; Youdim, MB | 1 |
| Bankiewicz, K; Finberg, JP; Goldstein, DS; Harvey-White, J; Kopin, IJ; Wang, J | 1 |
| Rascol, O | 1 |
| Ludin, HP | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Konitsiotis, S | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Schapira, AH | 1 |
| Burgut, FT; Henchcliffe, C; Schumacher, HC | 1 |
| Cochran, JM; Eckert, L; Hudry, J; Keränen, T; Rinne, JO | 1 |
| Eberly, SW; Goetz, CG; Oakes, D; Schwid, SR; Shoulson, I | 1 |
| Blindauer, K; Eberly, S; Elmer, L; Fahn, S; Goetz, C; Kieburtz, K; Oakes, D; Oren, S; Prisco, UL; Salzman, P; Schwid, S; Shoulson, I; Stern, M | 1 |
| Blindauer, K; deMarcaida, JA; Fahn, S; Kieburtz, K; Schwid, SR; Shoulson, I; Stern, M; White, WB | 1 |
| Keating, GM; Oldfield, V; Perry, CM | 1 |
| Chen, JJ; Fernandez, HH | 2 |
| Salzman, P; Schwid, SR; White, WB | 1 |
| Jost, WH; Klasser, M; Reichmann, H | 1 |
| Bertoni, JM; Elmer, LW | 1 |
| Fitzer-Attas, CJ; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Olanow, CW; Schapira, AH | 1 |
| Azulay, T; Brooks, DJ; Giladi, N; Melamed, E; Oertel, W; Poewe, WH; Rascol, O; Stocchi, F; Tal, J; Tolosa, E | 1 |
| Brotchie, J; Fitzer-Attas, C | 1 |
| Chuang, RS; Lang, AE | 1 |
| Reichmann, H | 1 |
| Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Auinger, P; Hauser, RA | 1 |
| Rabey, JM; Stocchi, F | 1 |
| Christine, CW; Marks, WJ; Ostrem, JL | 1 |
| Hoy, SM; Keating, GM | 1 |
| Belavic, J | 1 |
| Hoy, SM; Keating, GM; Lyseng-Williamson, KA | 1 |
| García-Ruiz, PJ; Luquin, MR | 1 |
| Olanow, CW | 1 |
| Pagonabarraga, J; Rodríguez-Oroz, MC | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Finberg, JP; Loboda, Y; Rabey, MJ; Sader-Mazbar, O | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Miklya, I | 1 |
| Cai, B; Cai, JP; Chen, WJ; Lin, Y; Wang, N | 1 |
| Habersack, A; Haehner, A; Hummel, T; Reichmann, H; Storch, A; Wienecke, M | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Grünblatt, E; Müller, T; Riederer, P | 1 |
| Assogna, F; Pontieri, FE; Rinaldi, D; Sforza, M; Tagliente, S | 1 |
| Cronin, A; Grealy, M | 1 |
| Hattori, N; Kato, M; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Hattori, N; Mochizuki, H; Nagai, M; Nakaya, R; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Wang, HK; Wang, Y | 1 |
| Chung, YA; Heo, Y; Im, JJ; Jeong, H; Oh, JK; Park, JS; Song, IU | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Parambi, DGT | 1 |
| Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Brotchie, J; Friedman, H; Giladi, N; Hauser, RA; Litman, P; Oren, S; Poewe, W | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Cao, S; Chen, H; Hu, X; Liang, Z; Liu, Z; Mao, W; Shao, M; Song, Z; Su, W; Tang, B; Wei, W; Wu, Y; Zhang, K | 1 |
| Gao, F; Gao, L; Miao, J; Yang, Y | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
27 review(s) available for levodopa and rasagiline
| Article | Year |
|---|---|
[Are there innovations in the treatment of Parkinson's disease?].
Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
Novel pharmacological strategies for motor complications in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2005 |
Rasagiline: a review of its use in the management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2007 |
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
Topics: Animals; Clinical Trials as Topic; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
Mechanisms compensating for dopamine loss in early Parkinson disease.
Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease | 2009 |
[Diagnosis and therapy of idiopathic Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease | 2012 |
[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Topics: Antiparkinson Agents; Attention; Clinical Trials as Topic; Cognition Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Fatigue; Headache; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Multicenter Studies as Topic; Nausea; Neuroprotective Agents; Parkinson Disease; Severity of Illness Index | 2013 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2015 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2020 |
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Topics: Humans; Indans; Levodopa; Parkinson Disease; Pramipexole | 2022 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
12 trial(s) available for levodopa and rasagiline
| Article | Year |
|---|---|
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Topics: Aged; Aged, 80 and over; Anorexia; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting; Weight Loss | 2005 |
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Topics: Aged; Behavioral Symptoms; Case-Control Studies; Cognition; Dopamine Agents; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease | 2006 |
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Food-Drug Interactions; Heart Rate; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Tyramine | 2006 |
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Food; Humans; Hypertension; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Postprandial Period; Supine Position; Telephone; Tyramine | 2008 |
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechols; Double-Blind Method; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Nitriles; Parkinson Disease; Principal Component Analysis; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires | 2009 |
Long-term efficacy of rasagiline in early Parkinson's disease.
Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Determination of minimal clinically important change in early and advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Placebo Effect; ROC Curve; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dysarthria; Facial Expression; Female; Humans; Hypokinesia; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Muscle Rigidity; Nitriles; Parkinson Disease; Severity of Illness Index; Tremor | 2011 |
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2018 |
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Treatment Outcome | 2019 |
34 other study(ies) available for levodopa and rasagiline
| Article | Year |
|---|---|
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
Pharmacology and neuroprotective properties of rasagiline.
Topics: Animals; Cells, Cultured; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Humans; Indans; Levodopa; Mesencephalon; Microdialysis; Mitochondria; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Rats; Tyrosine 3-Monooxygenase | 1996 |
Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Acid; Indans; Isoenzymes; Levodopa; Macaca mulatta; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 1998 |
Monoamine oxidase inhibitors--is it time to up the TEMPO?
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 2003 |
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Drug Utilization; Finland; Humans; Indans; Levodopa; Markov Chains; Models, Statistical; Parkinson Disease; Treatment Outcome | 2006 |
Safety of rasagiline in elderly patients with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Confusion; Disorders of Excessive Somnolence; Dopamine Agonists; Double-Blind Method; Female; Hallucinations; Humans; Hypotension, Orthostatic; Incidence; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic | 2006 |
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 2008 |
Drug selection and timing of initiation of treatment in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Indans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Time Factors | 2008 |
Rasagiline-induced spontaneous ejaculation.
Topics: Aged; Antiparkinson Agents; Ejaculation; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Sexual Behavior; Sexual Dysfunction, Physiological; Spinal Dysraphism | 2009 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Development of Parkinson's disease in patients with Narcolepsy.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain Stimulation; Dextroamphetamine; Female; Humans; Hypokinesia; Indans; International Classification of Diseases; Levodopa; Male; Middle Aged; Narcolepsy; Neuroprotective Agents; Parkinson Disease; Sleep; Young Adult | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Rasagiline: a guide to its use in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Medical therapy for Parkinson's disease--the current state of the art].
Topics: Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Basal Ganglia; Clorgyline; Dopamine; Dopamine Agents; Dopaminergic Neurons; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Indans; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organic Anion Transporters, Sodium-Independent; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine | 2014 |
Early Parkinson's disease patients on rasagiline present with better odor discrimination.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Discrimination, Psychological; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Odorants; Olfaction Disorders; Olfactory Perception; Parkinson Disease; Physical Stimulation; Prospective Studies; Psychophysics; Sensory Thresholds; Severity of Illness Index; Treatment Outcome | 2015 |
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome | 2017 |
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Executive Function; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Treatment Outcome | 2018 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline | 2019 |
Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2019 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
Topics: Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; East Asian People; Humans; Levodopa; Parkinson Disease; Prospective Studies; Treatment Outcome | 2023 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |